Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of Exenatide on Brain Glucose Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males age 18-65 years old~2. Patients must have Body Mass Index (BMI) between 25 and 40 kg/m2~3. 2-hour glucose concentration above 140mg/dl after 75g glucose load, ie, having impaired glucose tolerance or newly diagnosed type 2 diabetes.~4. Patients must have BMI of 25-40 kg/m2~5. Patients must have no known severe liver or kidney disease, cancer, neurologic, psychiatric or systemic disease, ability to understand the study.~6. Only patients whose body weight has been stable (±3-4 pounds) over the three months prior to study will be included.~7. Patients must have the following laboratory values:~   * Hematocrit ≥ 34 vol%~  * Serum creatinine\* ≤ 1.5 mg/dl in males and~  * Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT): ≤ 2.5 times upper limit of normal~  * Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT): ≤ 2.5 times upper limit of normal~  * Alkaline phosphatase ≤ 2.5 times upper limit of normal~  * If serum creatinine is ≤ 1.5 mg/dl in males, the PI can grant an exception and not exclude the patient if the Glomerular filtration rate (GFR) is \>70 ml/min~Exclusion Criteria:~Patients are excluded from participation in the study if they meet any of the following criteria:~1. Patients with major chronic illness (cancer, liver, kidney, cardiovascular disease)~2. Patients with BMI over 40 and under 25~3. Patient with age below 18 yrs and over 65 yrs~4. Female subjects~5. Patients with type 1 diabetes~6. Patients treated for type 2 diabetes~7. Subjects with normal glucose tolerance (NGT)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide first, then Placebo (Type: EXPERIMENTAL): Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
- Placebo first, then Exenatide (Type: EXPERIMENTAL): Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .

Based on this trial design, predict the completion outcome and termination type (if applicable).